Comparative Pharmacology
Head-to-head clinical analysis: CAMPATH versus XTANDI.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CAMPATH versus XTANDI.
CAMPATH vs XTANDI
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Alemtuzumab is a recombinant humanized monoclonal antibody that binds to CD52, a cell surface antigen expressed on B and T lymphocytes, NK cells, monocytes, and macrophages. Binding induces antibody-dependent cell-mediated cytotoxicity and complement-mediated lysis, resulting in prolonged lymphocyte depletion.
Androgen receptor inhibitor; binds to the androgen receptor, inhibits nuclear translocation, DNA binding, and transcription of androgen-responsive genes.
12 mg/day intravenously over 2 hours, administered for 5 consecutive days (total 60 mg). For patients with relapsed/refractory chronic lymphocytic leukemia (CLL), the recommended dose is 3 mg/day intravenously on day 1, 10 mg/day on day 2, and 30 mg/day on day 3 (dose escalation), followed by 30 mg/day three times per week on alternate days for up to 11 weeks (total cumulative dose up to 640 mg).
160 mg orally once daily.
None Documented
None Documented
Terminal half-life approximately 12 days (range 6-21 days) after repeated doses, supporting weekly dosing in CLL.
Enzalutamide: 5.8 days; active metabolite N-desmethyl enzalutamide: 7.8-8.6 days. Steady state achieved after ~28 days.
Clearance via opsonization and degradation in reticuloendothelial system; negligible renal or biliary excretion (<1% unchanged).
Primarily hepatic metabolism; 77% of dose recovered in feces (as metabolites), 15% in urine (as metabolites); less than 1% excreted unchanged.
Category C
Category C
Monoclonal Antibody, Antineoplastic
Antineoplastic